Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Structure Therapeutics Inc.GPCR · Entity 1222 | Chief Commercial Officer | August 06, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Structure Therapeutics Inc.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 140,766 |
Reported balance
After 2026-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-06 · Grant · Acquired 140,766 · Balance 140,766 F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2: Represents the grant of restricted share units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of August 6, 2026, subject to Reporting Person's continued service on such dates. |
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.54 · Expires 2036-08-05 | Direct | 174,612 |
Reported balance
After 2026-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-06 · Grant · Acquired 174,612 · Balance 174,612 F3: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4: One-fourth of the shares vest on the first anniversary of August 6, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
F2: Represents the grant of restricted share units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of August 6, 2026, subject to Reporting Person's continued service on such dates.
F3: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
F4: One-fourth of the shares vest on the first anniversary of August 6, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 7, 2026 20:08 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare option (right to buy) · Derivative | 174,612 | $0.00 Strike: $17.54 | $0.00 |
DisclosureSEC source: 0002148420-26-000006 · form4-08072026_080836.xml · derivative · entry 2 Berrios John Joseph · CIK 0002148420 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,612 Underlying: Ordinary Shares · 174,612 shares Expires 2036-08-05 F3 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4 · derivative.exercise_date: One-fourth of the shares vest on the first anniversary of August 6, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:08 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantOrdinary Shares | 140,766 | $0.00 | $0.00 |
DisclosureSEC source: 0002148420-26-000006 · form4-08072026_080836.xml · nonDerivative · entry 1 Berrios John Joseph · CIK 0002148420 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,766 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · kind: Represents the grant of restricted share units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of August 6, 2026, subject to Reporting Person's continued service on such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.